Key Drivers
- Cash Cushion
- Revenue Absence
- Burn Rate
AIAI Summary
KARD is now a clinical-execution story rather than a financing-risk story: its post-IPO cash runway reduces near-term distress, but with no revenue and a long wait for first-half-2027 data, the stock's upside hinges almost entirely on proving pipeline efficacy before burn and market patience run out.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Revenue Absence
- •Burn Rate
KARD has a very strong, low-debt cash position and meaningful asset backing, but no revenue, persistent losses, and negative free cash flow make it a high-burn, externally funded story. #cash-rich #high-burn
Price Behavior
Key Price Behavior Insights:
- •$20 support
- •Failed breakout
- •Lower high
KARD remains range-bound and slightly weak, with repeated support near $20 offset by failed rallies below $22.9 and price still under its last month average.
Sharp rally to $22.06 on 2026-08-11 quickly reversed to $20.20
Sentiment & News
Key News Insights:
- •Q2 Results
- •Business Update
- •Limited Catalysts
Kardigan's Q2 2026 update mainly refreshed investors on quarterly results and near-term business progress, with no major new catalysts.
The update is likely neutral for Kardigan, reinforcing visibility on execution but offering little immediate upside surprise
Similar Companies in Healthcare
Other companies in the same sector with AI ratings